newsfilter
← Latest News
GlobeNewswire·

Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson's Disease

Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson's Disease MLR-1019, a Phase 2-ready product, could have substantial benefits over today's Parkinson's drugs, in